Clinical Pearls on Tailoring Dosing Strategies in Metastatic Kidney Cancer

Video

David Aggen, MD, PhD, identifies dosing strategies that may maximize treatment efficacy while minimizing toxicity in patients with kidney cancer.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      Newsletter

      Stay up to date on recent advances in the multidisciplinary approach to cancer.

      Subscribe Now!
      Recent Videos
      Various methods of communication ensure that members from radiation oncology, pathology, and other departments are on the same page regarding treatment.
      Making a ‘World of Difference’ Via Multidisciplinary Care in GI, GU Cancers
      Comprehensive prehabilitation may help prepare patients for bladder-preserving surgery, helping to optimize quality of life outcomes.
      Reviewing QOL Strategies/Considerations Following Bladder Cancer Surgery
      Ongoing research suggests environmental exposures and the role of microbiomes may influence bladder cancer development and response to treatment.
      Outlining Risk Factor Identification and Mitigation in Bladder Cancer
      Episode 4: Adjuvant Therapy and Post-Surgical Management Options for Kidney Cancer
      Episode 4: Adjuvant Therapy and Post-Surgical Management Options for Kidney Cancer
      How a Radiation Oncologist Answers Patient Questions with Research
      How a Radiation Oncologist Answers Patient Questions with Research
      There Is Excitement and Advances in SBRT Treatment For RCC
      There Is Excitement and Advances in SBRT Treatment For RCC
      Radiation Oncology in Prostate Cancer Is Advancing Thanks to Technology and Time
      Radiation Oncology in Prostate Cancer Is Advancing Thanks to Technology and Time
      Strong Collaboration is Essential for Radiation Oncologists and Other Experts
      Strong Collaboration is Essential for Radiation Oncologists and Other Experts
      The Effect of Dato-DXd Targeting TROP2 in Urothelial Cancer
      The Effect of Dato-DXd Targeting TROP2 in Urothelial Cancer
      Disease Progression Links to QOL With Cemiplimab/Chemo in Penile Carcinoma
      Disease Progression Links to QOL With Cemiplimab/Chemo in Penile Carcinoma
      Related Content
      Time to deterioration in physical functioning and role functioning was similar among those receiving belzutifan vs everolimus for renal cell carcinoma.

      Belzutifan Improves Disease-Specific Symptoms/QOL vs Everolimus in RCC

      Roman Fabbricatore
      April 6th 2025
      Article

      Time to deterioration in physical functioning and role functioning was similar among those receiving belzutifan vs everolimus for renal cell carcinoma.

      Adjuvant Therapy and Post-Surgical Management Options for Kidney Cancer

      Adjuvant Therapy and Post-Surgical Management Options for Kidney Cancer

      Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
      April 1st 2025
      Podcast

      A recent Oncology Decoded podcast focuses on adjuvant therapy like pembrolizumab and optimal post-surgical care for patients with kidney cancer.

      A World of Research, Care, and Science: Becoming A Radiation Oncologist

      A World of Research, Care, and Science: Becoming A Radiation Oncologist

      Tim Cortese
      March 12th 2025
      Article

      James B. Yu, MD, MHS, FASTRO, didn’t always envision himself as a radiation oncologist, but now works tirelessly to treat patients and advance research for genitourinary cancers.

      Traversing the Complexities of Non-Clear Cell Renal Cell Carcinoma

      Traversing the Complexities of Non-Clear Cell Renal Cell Carcinoma

      Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Stephanie A. Berg, DO
      March 7th 2025
      Podcast

      A brief overview of the current RCC landscape was provided in the most recent Oncology Decoded podcast.

      Longer progression-free survival and more enduring responses occurred with avelumab/axitinib vs sunitinib in the phase 3 JAVELIN Renal 101 trial.

      Avelumab Combo Improves Long-Term Efficacy Vs Sunitinib in Advanced RCC

      Russ Conroy
      February 26th 2025
      Article

      Longer progression-free survival and more enduring responses occurred with avelumab/axitinib vs sunitinib in the phase 3 JAVELIN Renal 101 trial.

      Data presented at 2025 ASCO GU reinforce the use of agents like nivolumab, cabozantinib, and darolutamide across different genitourinary malignancies.

      Top 5 Takeaways for Genitourinary Cancer Care From 2025 ASCO GU

      Russ Conroy
      February 21st 2025
      Article

      Data presented at 2025 ASCO GU reinforce the use of agents like nivolumab, cabozantinib, and darolutamide across different genitourinary malignancies.